Acorda Therapeutics and Watson Pharma, a subsidiary of Watson Pharmaceuticals, have collaborated to introduce tizanidine hydrochloride capsules, an authorized generic version of zanaflex capsules (tizanidine hydrochloride).
Subscribe to our email newsletter
Acorda will receive a royalty from Watson based on product sales.
Additional terms of the agreement have not been disclosed.
Tizanidine hydrochloride capsule is a short-acting drug indicated for the management of spasticity.
Because of the short duration of effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important, Acorda said.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.